A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Greater Sudbury, Mississauga, Montreal, North Bay, Saskatoon, Surrey, and Vancouver, CanadaSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT07037901, who can take part
Where in Canada
- Greater SudburyGreater Sudbury, CanadaTaking people
- MississaugaMississauga, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- North BayNorth Bay, CanadaTaking people
- SaskatoonSaskatoon, CanadaTaking people
- SurreySurrey, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Inmagene LLC
- Trial code
- NCT07037901EU 2024-520117-50-00
- Record updated
- 12 August 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.Read full original descriptionShow less
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Inclusion: Moderate-to-severe AD; Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable; Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception; Male participants must agree to use a highly effective method of contraception; EASI score ≥16; vIGA-AD score ≥3; ≥10% body surface area (BSA) of AD involvement; Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization.
Exclusion: Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals; Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit; Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection; Evidence of active or latent tuberculosis (TB); History of untreated or inadequately treated TB infection; Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement; Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.